In non–small cell lung cancer (NSCLC), CD40 agonists used as monotherapy or in combination with immune checkpoint inhibitors have led to stable disease in a subset of patients, while enhancing dendritic cell function and T cell priming (190, 191). The gene discussed is CD40; the disease is non-small cell lung carcinoma.